Abstracts

Low-dose aspirin in combination with transarterial chemoembolization in treatment of unresectable hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is the sixth and fourth common cancer in worldwide and Egypt. Transarterial chemoembolization (TACE) is standard treatment for ...

06/27/2022

Blood plasma mRNA sequencing for monitoring therapy response in esophageal adenocarcinoma patients

Background The incidence of esophageal adenocarcinoma (EAC), a histological subtype of esophageal cancer, has rapidly increased in the Western world in the last decades....

06/27/2022

Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301)

Background Immune checkpoint blockade (ICB) is minimally active in unselected pancreaticobiliary cancer (PBC) patients. Treatment regimens combining ICI with agents that...

06/27/2022

A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers

Background Activation of the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2) induces apoptosis via the extrinsic pathway. Targeting TRAILR2 ...

Eric Van Cutsem , MD, PhD;

06/27/2022

EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts

Background Gastroesophageal cancers, including esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma and g...

06/27/2022

Bevacizumab in metastatic colorectal carcinoma: A retrospective review of real-world efficacy

Background We present to you a retrospective review of our institutional use of Bevacizumab in colorectal cancer with respect to chemotherapeutic regimen, efficacy and m...

Paul Farrugia ;

Malcolm Buhagiar ;

Christopher Portelli ;

06/27/2022

Discriminating factors for gastric neoplasm among regenerative atypia found in screening upper gastrointestinal endoscopy

Background In screening endoscopy, biopsies for suspicious malignant lesions often show a diagnosis of regenerative atypia which makes it difficult to make clinical deci...

06/27/2022

Circulating tumor DNA in metastatic colorectal cancer: Real-time monitoring of disease evolution and treatment response

Background Colorectal cancer (CRC) is the third most common cancer worldwide and ranks second in terms of mortality. Approximately 20% of CRCs are diagnosed in the metas...

06/27/2022

Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study

Background Despite recent advances in the treatment of mCRC, the survival benefit obtained with third-line treatment is modest. Anti-EGFR therapy does not provide surviv...

06/27/2022

Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102

Background International guidelines recommend the use of Regorafenib or TAS 102 from third line of treatment in metastatic colorectal cancer (mCRC). Retrospective analys...

06/27/2022